Some features of the coronavirus infection course in bronchial asthma patients
- Authors: Kharitonov M.A.1, Burkova Y.S.2, Salukhov V.V.2, Sapronova A.S.2
-
Affiliations:
- Military medical academy of S.M. Kirov
- Military Medical Academy of S.M. Kirov
- Issue: Vol 24, No 3 (2022)
- Pages: 537-546
- Section: Review
- URL: https://journals.rcsi.science/1682-7392/article/view/108519
- DOI: https://doi.org/10.17816/brmma108519
- ID: 108519
Cite item
Abstract
The outbreak of a new coronavirus infection was officially recognized by the World Health Organization as a global pandemic since March 11, 2020. The pandemic is currently gradually receding, the number of patients is also steadily decreasing. However, these circumstances are not grounds to believe that the virus has been definitively and irrevocably defeated. For this reason, the world medical community is still concerned about the coronavirus’ impact on the course and outcome of various chronic bronchopulmonary diseases. Bronchial asthma has been recognized as one of the leading forms of human somatic pathology throughout the history of mankind and medicine. It is quite natural that the focus of the researchers' attention turned out to be questions about the SARS-CoV-2 virus’ impact on patients suffering from bronchial asthma, starting with the peculiarities of the course of combined pathology and ending with the peculiarities of therapy and subsequent rehabilitation. The issues of coronavirus infection and bronchial asthma pathogenesis were considered. The research data on some features of the development and course of a new coronavirus infection in patients with this profile were analyzed and summarized. The low coronavirus infection prevalence among patients with an allergic bronchial asthma form compared with other phenotypes is shown among such features, data on the effect of eosinophilia on the course of infection are presented, and the basic therapy’s positive effect using inhaled glucocorticosteroids and/or monoclonal antibodies (biological therapy) in severe asthma, is shown in the form of a protective effect that provides a lighter coronavirus infection course. The main features of patient management suffering from bronchial asthma in the conditions of a pandemic are the organization of stable medical control in online telemedicine once monthly, regular examinations in accordance with the severity of the course of the disease and the correction of basic therapy to achieve complete control over the course of asthma.
Full Text
##article.viewOnOriginalSite##About the authors
Mikhail A. Kharitonov
Military medical academy of S.M. Kirov
Email: micjul11@yandex.ru
ORCID iD: 0000-0002-6521-7986
SPIN-code: 7678-2278
Doctor of Medical Sciences, Professor
Russian Federation, Saint PetersburgYulia S. Burkova
Military Medical Academy of S.M. Kirov
Author for correspondence.
Email: sjs81@mail.ru
ORCID iD: 0000-0002-0276-9863
SPIN-code: 8240-3729
Candidate of Medical Sciences
Russian Federation, Saint PetersburgVladimir V. Salukhov
Military Medical Academy of S.M. Kirov
Email: vlasaluk@yandex.ru
ORCID iD: 0000-0003-1851-0941
SPIN-code: 4531-6011
Doctor of Medical Sciences
Russian Federation, Saint PetersburgAnastasia S. Sapronova
Military Medical Academy of S.M. Kirov
Email: sapronova.nastya@bk.ru
ORCID iD: 0000-0003-2742-7904
SPIN-code: 3901-5972
Russian Federation, Saint Petersburg
References
- Ochani RK, Asad A, Yasmin F, et al COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infections in Medicine. 2021;29(1):20–36.
- Fisun AYa, Aganov DS, Bazilevich SN. COVID-19 i zabolevaniya vnutrennikh organov: osobennosti vedeniya patsientov. Vremennye klinicheskie rekomendatsii. 2020. P. 131–144. (In Russ.).
- Salukhov VV, Kovalevskaya EA. Vitamin D is a strategic blow to coronavirus infection. Medical Council. 2020;(21):218–228. (In Russ.). doi: 10.21518/2079-701X-2020-21-218-228
- Broadhurst R, Peterson R, Wisnivesky JP, et al. Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? Ann Am Thorac Soc. 2020;17(12):1645–1648. doi: 10.1513/AnnalsATS.202006-613RL
- Sunjaya AP, Allida SM, Di Tanna GL, Jenkins CR. Asthma and Coronavirus Disease 2019 Risk: a systematic review and meta-analysis. Eur Respir J. 2021;14(2):210. doi: 10.1183/13993003.01209-2021
- Caminati M, Vultaggio A, Matucci A, et al. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;176(7):106261. doi: 10.1016/j.rmed.2020.106261
- Avdeev SN, Nenasheva NM, Zhudenkov KV, et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya. 2018;28(3):341–358. (In Russ.). doi: 10.18093/0869-0189-2018-28-3-341-358
- Salukhov VV, Kharitonov MA, Kryukov EV, et al. Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. Medical Council. 2020;(21):96–102. (In Russ.). doi: 10.21518/2079-701X-2020-21-96-102
- Rudakov JV, Mitin JA. The immunology special features of bronchial asthma in the patients, with the debut of disease at the age are older than 60 years. Bulletin of the Russian Military Medical Academy. 2009;(1):94–96. (In Russ.).
- Trushina EYu, Kostina EM, Orlova EA. Patients with bronchial asthma who have undergone COVID-19. Farmateka. 2021;(5):76–80. (In Russ.). doi: 10.18565/pharmateca.2021.5.76-80
- Fedoseev GB, Trofimov VI. Bronkhial'naya astma. Saint Petersburg: Normedizdat, 2006. 308 p. (In Russ.).
- Kharitonov MA, Salukhov VV, Kryukov EV, et al. Viral pneumonia: a new look at an old problem (review). Medical Council. 2021;(16): 60–77. (In Russ.). doi: 10.21518/2079-701X-2021-16-60-77
- Kalinichenko UYu, Shvarts VD. Koronavirusnaya infektsiya COVID-19 I BA. Forcipe. 2021;4(1):833–834. (In Russ.).
- Gaisina AR, Shilovskiy IP, Nikonova AA, et al. The study of balance of Th1/Th2 immune response during virus-induced asthma exacerbation. Russian Journal of Allergy. 2016;13(4–5):20–28. (In Russ.). doi: 10.36691/RJA347
- Asiryn EG, Matyuschenko OV, Matsuk ON. Pathogenetic aspects of bronchial asthma. Maternal and child health. 2020;(1):102–107. (In Russ.).
- Tsai S-C, Lu C-C, Bau D-T, et al. Approaches towards fighting the COVID-19 pandemic (Review). Int J Mol Med. 2021;47(1):3–22. doi: 10.3892/ijmm.2020.4794
- Osipova VV, Osipova GL, Zaryanova EA, Terekhov DV. Asthma and COVID-19: Аn overview of the guidelines for the management of asthma patients during the COVID-19 pandemic. Pulmonologiya. 2021;31(5): 663–670. (In Russ.). doi: 10.18093/0869-0189-2021-31-5-663-670
- Nenasheva NM. Fenotipy bronkhial'noi astmy i vybor terapii. Prakticheskaya pul'monologiya. 2014;(2):2–11. (In Russ.).
- Ovsyannikov ES, Аvdeev SN, Budnevskiy AV, et al. Bronchial Asthma and COVID-19: Comorbidity Issues. Tuberculosis and Lung Diseases. 2021;99(9):6–14. (In Russ.). doi: 10.21292/2075-1230-2021-99-9-6-14
- Choi YJ, Park J-Y, Lee HS, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021;57(3):2226. doi: 10.1183/13993003.02226-2020
- Anka AU, Tahir MI, Abubakar SD, et al. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2020;6(2):1298. doi: 10.1111/sji.12998
- Val'chuk IN. Sovremennye problemy ostrykh respiratornykh infektsii i bronkhial'noi astmy: sbornik nauchnykh trudov Belorusskogo gosudarstvennogo meditsinskogo universiteta. T. 1. Minsk: GU RNMB, 2011. P. 7. (In Russ.).
- Nicholson K, Kent J, Ireland D. Respiratory viruses and exacerbations of asthma in adults. BMJ . 1993;3079(6910):982–986. doi: 10.1136/bmj.307.6910.982
- Ayoubkhani D, Khunti K, Nafilyan V, Maddox T. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372(49):693. doi: 10.1136/bmj.n693
- Global Initiative for Asthma. GINA guidance about COVID-19 and asthma 2022. 223 р.
- Green I, Merzon E, Vinker S, Golan-Conen A. COVID-19 Susceptibility in Bronchial Asthma. J Allergy Clin Immunol Pract. 2021;9(2):684–692. doi: 10.1016/j.jaip.2020.11.020
- Izquierdo JL, Almonacid C, Gonzalez Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021;57(3):2142. doi: 10.1183/13993003.03142-2020
- Rosenberg HF, Foster PS. Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies. Semin Immunopathol. 2021;43(3):383–392. doi: 10.1007/s00281-021-00850-3
- Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75(11):2829–2845. doi: 10.1111/all.14429
- Skevaki C, Karsonova A, Karaulov A, et al. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol. 2020;146(6):1295–1301. doi: 10.1016/j.jaci.2020.09.017
- Wark PAB, Pathinayake PS, Eapen MS, Sohal SS. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights. Eur Respir J. 2021;58(2):2100920. doi: 10.1183/13993003.00920-2021
- Gagne M, Cheung JLS, Kouri A, et al. A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm. Respir Med. 2021:106568. doi: 10.1016/j.rmed.2021.106568
- Davido B, Partouche B, Jaffal K, et al. Eosinopenia in COVID-19: What we missed so far? J Microbiol Immunol Infect. 2021;54(5): 1006–1007. doi: 10.1016/j.jmii.2021.01.013
- Lieberman-Cribbin W, Rapp J, Alpert N, et al. The Impact of Asthma on Mortality in Patients With COVID-19. Chest. 2020;158(6):2290–2291. doi: 10.1016/j.chest.2020.05.575
- Gasmi A, Peana M, Pivina L, et al. Interrelations between COVID-19 and other disorders. Clin Immunol. 2021;224(28):108. doi: 10.1016/j.clim.2020.108651
- Peredel'skaya MYu, Nenasheva NM. BA i COVID-19: chto izvestno o sochetanii dvukh diagnozov u odnogo bol'nogo. Astma i allergiya. 2021;(2):3–8. (In Russ.).
- Zhang J-J, Dong X, Cao Y-Y. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7): 1730–1741. doi: 10.1111/all.14238
- Zhao L, Zhang Y-P, Yang X, Liu X. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019. Allergy. 2021;76(2):562–564. doi: 10.1111/all.14455
- Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155–168. doi: 10.1016/j.resinv.2019.12.005
- Agusti A, Torres F, Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respir Med. 2021;9(7):682–683. doi: 10.1016/S2213-2600(21)00171-5
- Khludova LG. BA i COVID-19. Astma i allergiya. 2020;(1):3–5. (In Russ.).
- Hojo M, Terada-Hirashima J, Sugiyama H. COVID-19 and bronchial asthma: current perspectives. Global Health and Medicine. 2021;3(2):67–72. doi: 10.35772/ghm.2020.01117
- Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543–1545. doi: 10.1111/all.14348
- Riegel B, Westland H, Iovino P, et al. Characteristics of self-care interventions for patients with a chronic condition: A scoping review. Int J Nurs Stud. 2021;116(2):103713. doi: 10.1016/j.ijnurstu.2020.103713
- Eger K, Bel EH. Asthma and COVID-19: do we finally have answers? Eur Respir J. 2021;57(3):2004451. doi: 10.1183/13993003.04451-2020
- Heffler E, Detoraki A, Contoli M, et al. COVID-19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments. Allergy. 2020;15(4):111–123. doi: 10.22541/au.159335800.09668428
- Denneny EK, Garthwaite HS, Heightman MJ, Porter JC. A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up? Ann Am Thorac Soci. 2021;18(6):1082–1083. doi: 10.1513/AnnalsATS.202101-048LE
- Tabatabaian F, Ledford DK. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy. 2018;11(5):53–61. doi: 10.2147/JAA.S107982
- Petrov DV, Belevskii AS. Vedenie patsientov s bronkhial'noi astmoi v usloviyakh pandemii COVID-19. Astma i allergiya. 2020;(1):6–11. (In Russ.).
- Fomina DS, Serdotetskova SA, Ivanova MS, et al. Management of patients with COVID-19 and asthma: literature review and clinical experience of the authors. Prakticheskaya pul'monologiya. 2020;(2):3–15. (In Russ.).
- Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772. doi: 10.1016/S2213-2600(21)00160-0